

SAFETY DATA SHEETS

This SDS packet was issued with item:

078678741

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078062881 078678733

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078678725 078678758



Product Name: Panolog[®] Ointment

Page No: 1 of 4

Date of issue: August 2008

MATERIAL SAFETY DATA SHEET

Section 1 - Identification of Chemical Product and Company

COMPANY DETAILS:

Novartis Animal Health Australasia Pty Limited
A.C.N. 076 745 198
54 Waterloo Road
North Ryde NSW 2113

Phone: (02) 9805 3555

Fax: (02) 9888 8387

Product Name: Panolog[®] Ointment
Active Ingredients: Nystatin, Neomycin sulfate, Triamcinolone acetonide and Thiostrepton
Ciba-Geigy Code : Nystatin (CGA 228921), Neomycin sulfate (CGA 77093),
Triamcinolone acetonide (CGA 228918), Thiostrepton (CGA 344267)
Product Use: For treatment of most skin and ear infections in dogs and cats.
Revision Date: August 2008

Section 2 Hazards Identification

Hazard classification: Hazardous Substance (NOHSC criteria)
Non-Dangerous Goods
Safety Phrases: None
SUSDP Classification: 4
UN Number: None Allocated

Section 3 Composition / Information on Ingredients

Ingredients	CAS No.	Content (/ml)
Triamcinolone acetonide	[76-25-5]	1.0 mg
Neomycin sulphate	[1405-10-3]	3.8 mg
Thiostrepton	[1393-48-2]	2500 IU
Nystatin	[1400-61-9]	100 000 IU
Plastibase 10W	-	to 1.0 ml

This is a commercial product whose exact ratio of components may vary slightly.

Section 4 First Aid Measures

Label regulated First Aid Statement: If poisoning occurs contact a Doctor or Poisons Information Centre (Phone 131126).
Scheduled poisons : Product is an S₄ scheduled poison. Poisons Information Centres in each State capital city can provide additional assistance for scheduled poisons (Phone 131126).
Skin Contact: Wash affected areas thoroughly with soap and water.
Eye contact: Flush gently with large quantities of clean tap water for several minutes.
Swallowed: Seek medical advice if the patient does not improve within 2-3 hours. Repeatedly administer medicinal charcoal in a large quantity of water. Note: Never give anything by mouth to an unconscious person. Do not induce vomiting. Give patient plenty of water to drink.
Advice to doctor: No specific treatment is known. Treat symptomatically

Section 5 Fire Fighting Measures

Extinguishing Media: This product is non-flammable and non-explosive.
Use extinguishing media suited to the materials that are burning such as

Novartis Animal Health Australasia Pty Ltd

MATERIAL SAFETY DATA SHEET**Fire Fighting:**

powder, foam, carbon dioxide or water-spray (do not use direct jet water).

Fight fire in the early stages if safe to do so. Combustion products are toxic and/or irritant. Use appropriate protective equipment when fire fighting.

Section 6 Accidental Release Measures**Accidental Release:**

In case of spillage it is important to take all steps necessary to:
Avoid eye and skin contact. Avoid contamination of surface and ground water, drainage systems and other waterways.

Procedure for spill:

Wear personal protective equipment as described above. Cover spilled product with an absorbent such as sand, soil or diatomaceous earth. Collect material in specially marked tightly closed containers. Clean contaminated areas with carbonated or soapy water. Put washing water in containers too, to avoid any contamination of surface and ground water, water supplies and drains. Hose down the area for a prolonged period. Heavily contaminated soil layers have to be dug out down to clean soil. Spilled product cannot be re-used. If safe disposal is not possible, contact the manufacturer or reseller and dispose of in an incinerator approved for chemicals

Section 7 Handling and Storage**Safe Handling:**

Keep out of reach of children. Wash hands after use.

Storage:

Store below 25°C (Air Conditioning) in original tightly sealed container. Store away from direct sunlight and humidity.

Section 8 Exposure Controls / Personal Protection**Exposure Limits:**

No occupational exposure limits TWA or STEL have been set for the ingredients of this product.

Eye Protection:

No special protective equipment normally required.

Skin protection:

No special protective equipment normally required.

Respirator:

No special protective equipment normally required.

General advice:

No personal protective equipment is considered necessary for handling Panolog to treat animals.

Section 9 - Physical and Chemical Properties**Physical State:**

Ointment

Colour:

Yellow - amber

Odour:

Characteristic

pH (20-25°C):

5.2 - 7.2

Corrosiveness:

Non-corrosive

Flammability:

Non-flammable

Flashpoint:

154°C

Specific gravity (25°C):

0.885 g/cm³

Viscosity (20°C):

1500-5500 mPa

Solubility in water (20°C):

Insoluble

MATERIAL SAFETY DATA SHEET**Section 10 - Stability and Reactivity**

Chemical Stability: Product is stable under normal conditions.

Section 11 - Toxicological Information

Acute Toxicity : Acute toxic effects are very unlikely, since Panolog is used topically and most ingredients are absorbed poorly through the skin. Also, accidental ingestion should not be a major hazard since most ingredients are also poorly absorbed from the gastrointestinal tract (except triamcinolone acetonide which is of very low oral toxicity).

Oral: Low toxicity. Oral toxicity for the active ingredients are;
Nystatin LD₅₀ = 10000 mg/kg (rat) and 8000 mg/kg (mouse).
Thiostrepton LD₅₀ > 10000 mg/kg (mouse).
Neomycin sulphate LD₅₀ = 2750 mg/kg (rat)
Triamcinolone acetonide LD₅₀ = 5000 mg/kg.

Local Effects: Irritation - (Based on studies on Rabbits)

Skin and Eyes: Non-irritant

Chronic Toxicity: Prolonged use could result in some toxic effects, especially due to dermal penetration of triamcinolone acetonide.

Section 12 - Ecological Information

Ecological data for Panolog: Panolog is toxic to Bacteria based upon the active ingredients.

Section 13 - Disposal Considerations

After intended use: Dispose of empty, used containers by wrapping in paper and putting in garbage.

Section 14 - Transport Information

UN Number: None allocated
UN proper shipping name: None allocated
Class & Subsidiary Risk : None allocated
Packaging Group: None allocated
HAZCHEM Code: None allocated

Section 15 - Regulatory Information

Australia: Product registered for use with the Australian Pesticides and Veterinary Medicines Authority

Section 16 - Other Information

This MSDS contains only safety-related information. For other data see product literature.

Acronyms

CAS Number: Chemical Abstracts Service Registry Number
Hazchem Number: Emergency action code of numbers and letters that provide information to emergency services especially fire-fighters
NOHSC: National Occupational Health and Safety Commission
STEL: Short-term Exposure Limit
SUSDP: Standard for the Uniform Scheduling of Drugs & Poisons



Product Name: Panolog[®] Ointment

Page No: 4 of 4

Date of issue: August 2008

MATERIAL SAFETY DATA SHEET

TWA: Time Weighted Average
UN Number: United Nations Number

This product is a registered veterinary chemical and must therefore be used in accordance with the container label directions. A comprehensive package of toxicological and environmental data for the active ingredients of this product has been submitted to the Federal health and environment authorities and has been evaluated by expert toxicologists and environmental scientists.

This Material Safety Data Sheet summarises our best knowledge of the health and safety hazard information of the product and how to safely handle and use the product in the workplace. Each user should read this MSDS and consider the information in the context of how the product will be handled and used in the workplace including in conjunction with other products.

If clarification or further information is needed to ensure that an appropriate risk assessment can be made, the user should contact this company.

® Registered Trade Mark of Novartis AG. Basel, Switzerland

SAFETY DATA SHEET



Revision date: 26-Mar-2014

Version: 2.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment

Trade Name: PANALOG OINTMENT

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as Antifungal, antibacterial, anti-inflammatory and antipruritic

Details of the Supplier of the Safety Data Sheet

Zoetis Inc.

100 Campus Drive, P.O. Box 651
Florham Park, New Jersey 07932 (USA)
Rocky Mountain Poison Control Center Phone: 1-866-531-8896
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.

Mercuriusstraat 20
1930 Zaventem
Belgium

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Yellow ointment

Classification of the Substance or Mixture

GHS - Classification

Respiratory Sensitization: Category 1

Skin Sensitization: Category 1

Reproductive Toxicity: Category 1B

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Danger

Hazard Statements: H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

H317 - May cause an allergic skin reaction

H360 - May damage fertility or the unborn child

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 2 of 10

Version: 2.0

Precautionary Statements:

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P284 - Wear respiratory protection
P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P362 - Take off contaminated clothing and wash before reuse
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards

Short Term:

Known Clinical Effects:

May be absorbed through the skin and cause systemic effects.
Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes.
Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Neomycin Sulfate	1405-10-3	215-773-1	Xn;R42/43 Repr.Cat.3;R63	Resp. Sens. 1 (H334) Skin Sens.1(H317) Repro. 2 (H361) Aq. Acute 3 (H402) Aq. Chronic 3 (H412)	<1.0
Triamcinolone acetonide	76-25-5	200-948-7	Repr.Cat.2;R61	Repr. 1B (H360)	<1.0
Thiostrepton	1393-48-2	215-734-9	Not Listed	Not Listed	<1.0
Nystatin	1400-61-9	215-749-0	Not Listed	Not Listed	<1.0

PZ01565

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 3 of 10

Version: 2.0

3. COMPOSITION/INFORMATION ON INGREDIENTS

Mineral oil, heavy	8042-47-5	232-455-8	Not Listed	Not Listed	<1.0
--------------------	-----------	-----------	------------	------------	------

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions: None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Dike and collect water used to fight fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 4 of 10

Version: 2.0

Measures for Cleaning / Collecting:

Contain the source of the spill or leak. Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal. Clean spill area thoroughly.

Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Neomycin Sulfate

Zoetis OEL TWA 8-hr 100 µg/m³, Sensitizer

Triamcinolone acetonide

Zoetis OEL TWA 8-hr 4µg/m³, Skin

Mineral oil, heavy

ACGIH Threshold Limit Value (TWA) 5 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Nystatin

Zoetis OEB OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Wear impervious gloves if skin contact is possible.

Eyes:

Safety glasses or goggles

Skin:

Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

Respiratory protection:

If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 5 of 10

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Ointment	Color:	Yellow
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)	No data available		
Neomycin Sulfate			
Predicted 7.4 Log D 1.20			
Triamcinolone acetonide			
Predicted 7.4 Log D 2.5			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):	No data available		
Flammability (Solids):	No data available		
Flash Point (Liquid) (°C):	No data available		
Upper Explosive Limits (Liquid) (% by Vol.):	No data available		
Lower Explosive Limits (Liquid) (% by Vol.):	No data available		
Polymerization:	Will not occur		

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been investigated. The information included in this section describes the potential hazards of the individual ingredients.

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 6 of 10

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Neomycin Sulfate

Rat Oral LD 50 2750 mg/kg
Mouse Oral LD 50 2880mg/kg
Mouse Intraperitoneal LD 50 116mg/kg
Rat Subcutaneous LD 50 633mg/kg
Mouse Subcutaneous LD 50 275mg/kg

Nystatin

Rat Oral LD50 10,000 mg/kg

Triamcinolone acetonide

Rat Subcutaneous LD50 13100 ug/kg
Mouse Oral LD50 5g/kg
Mouse Subcutaneous LD50 132mg/kg
Rabbit Dermal LD50 > 402mg/kg
Rat Oral LD50 5g/kg

Thiostrepton

Mouse Oral LD50 > 1000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene glycol

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Neomycin Sulfate

Skin Irritation Rabbit Moderate
Eye Irritation Rabbit Minimal
Skin Sensitization Positive

Triamcinolone acetonide

Skin Irritation Rabbit Negative
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Neomycin Sulfate

6 Week(s) Dog Oral 100 mg/kg/day NOAEL No effects at maximum dose
3 Month(s) Guinea Pig Oral 10 mg/kg/day NOAEL No effects at maximum dose
3 Month(s) Dog Subcutaneous 20 mg/kg/day LOAEL Kidney
12 Month(s) Cat Oral 12 mg/kg/day NOAEL Blood forming organs
3 Month(s) Guinea Pig Subcutaneous 10 mg/kg/day LOAEL Kidney

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 7 of 10

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Neomycin Sulfate

Reproductive & Fertility	Mouse	Oral	4000 mg/L	NOAEL	No effects at maximum dose
2 Generation Reproductive Toxicity	Rat	Oral	25 mg/kg/day	NOAEL	Fetotoxicity
Reproductive & Fertility	Rat	Oral	25 mg/kg/day	NOAEL	No effects at maximum dose
Prenatal & Postnatal Development	Rat	Subcutaneous	6 mg/kg/day	LOAEL	Developmental toxicity

Triamcinolone acetonide

Embryo / Fetal Development	Mouse	Intramuscular	10 mg/day	LOAEL	Fetotoxicity, Teratogenic
Embryo / Fetal Development	Rat	Intramuscular	0.5 mg/kg/day	LOAEL	Teratogenic
Embryo / Fetal Development	Monkey	Intramuscular	0.5 mg/kg	LOAEL	Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Neomycin Sulfate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
Mammalian Cell Mutagenicity	Chinese Hamster Ovary (CHO) cells	Negative
<i>In Vivo</i> Cytogenetics	Mouse	Negative
<i>In Vitro</i> Chromosome Aberration	Human Lymphocytes	Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Neomycin Sulfate

2 Year(s)	Rat	Oral	25 mg/kg/day	NOAEL	Not carcinogenic
-----------	-----	------	--------------	-------	------------------

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 8 of 10

Version: 2.0

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Neomycin Sulfate

<i>Daphnia magna</i> (Water Flea)	OECD	EC50	48 Hours	68 mg/L
<i>Salmo gairdneri</i> (Trout)	OECD	NOEC	96 Hours	>1000 mg/L

Neomycin Sulfate

Activated sludge	OECD	EC50	399 mg/L
------------------	------	------	----------

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Neomycin Sulfate

Predicted	7.4	Log D	1.20
-----------	-----	-------	------

Triamcinolone acetonide

Predicted	7.4	Log D	2.5
-----------	-----	-------	-----

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-
Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 9 of 10

Version: 2.0

15. REGULATORY INFORMATION

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A

Class D, Division 2, Subdivision B

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.



Neomycin Sulfate

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

developmental toxicity initial date 10/1/92 internal use

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

215-773-1

Triamcinolone acetonide

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

200-948-7

Thiostrepton

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 4

EU EINECS/ELINCS List

215-734-9

Nystatin

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Australia (AICS):

Present

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 2

Schedule 3

Schedule 4

EU EINECS/ELINCS List

215-749-0

Mineral oil, heavy

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Inventory - United States TSCA - Sect. 8(b)

Present

Australia (AICS):

Present

EU EINECS/ELINCS List

232-455-8

SAFETY DATA SHEET

Material Name: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment
Revision date: 26-Mar-2014

Page 10 of 10

Version: 2.0

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H317 - May cause an allergic skin reaction
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
H360 - May damage fertility or the unborn child
H361 - Suspected of damaging fertility or the unborn child
H402 - Harmful to aquatic life
H412 - Harmful to aquatic life with long lasting effects

Toxic to Reproduction: Category 2
Xn - Harmful

R61 - May cause harm to the unborn child.
R63 - Possible risk of harm to the unborn child.
R42/43 - May cause sensitization by inhalation and skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet